Leen Kawas Leading the Way With Propel Bio Partners

Leen Kawas, a co-founder of Athira Pharma, has launched a new company.

As the new co-founder and managing general partner of Propel Bio Partners LP, Kawas will continue her goal to support innovation and express her commitment to helping like-minded entrepreneurs in the medical field.

Operating from headquarters in both Los Angeles and Seattle, Propel Bio Partners LP is an equity investment business with a global reach that will be investing in life sciences firms developing breakthrough medicines and technologies to improve human health.

Also read: Dr. Leen Kawas on Improving Clinical Trials to Get Quality Data

About Dr. Leen Kawas

Dr. Leen Kawas graduated from the University of Jordan with a bachelor’s degree in pharmacy.

She subsequently moved to the United States, where she went on to earn her Ph.D. in molecular pharmacology from Washington State University.

Later, she co-founded M3 Biotechnology, the same company that later became Athira Pharma.

The firm specialized in creating effective treatments for neurodegenerative disorders like Alzheimer’s.

Dr. Kawas was chosen president and CEO of Athira in 2014, and she served on the company’s board of directors until 2021.

During her tenure, Kawas co-invented numerous medications in Athira Pharma’s pipeline, including Alzheimer’s and Parkinson’s disease therapeutics.

She created the firm from the ground up in just six years, steering it through the early phases of drug research, its IPO, and the last stages of creating potentially life-changing medicines.

Dr. Kawas became the first female CEO of a biotech business to go public in Washington State in over 20 years.

The Mission of Propel Bio Partners and Its First Raise

Propel’s Bio Partners goal is to help life sciences firms that are working to improve people’s quality of life and change the way they get care, through revolutionary medicines and technology.

Propel will invest in businesses at all stages of development, from early-stage to late stage.

The financial investment will not be the only source of support for these businesses.

Propel will also provide access to medical specialists, operational advisers, and service suppliers to help its portfolio firms’ founders and management teams.

These materials will focus on key parts of the development process at all phases of development, with a focus on quality and efficiency.

Kawas is ecstatic to be able to provide young, enthusiastic entrepreneurs the same chance that others offered her when she founded Athira.

Propel has the backing of a number of other Athira investors, including Carol Criner, a strategy and operations specialist who has joined Propel’s advisory board.

The advisory board will help with opportunity evaluation, and Propel’s portfolio firms will have access to this group of seasoned professionals.

Senior associate Dasom (Christine) Yoo, a former business development manager at the Fred Hutchinson Cancer Research Center, is also part of Propel Bio’s team.

Propel Bio is seeking to raise $150 million in a pooled investment fund, according to a recent filing with the Securities and Exchange Commission.

If Propel’s early investors’ enthusiastic words are any indicator, it’s a goal that the company can achieve.

Propel Bio Partners is expected to inspire innovation and improvement in healthcare, with Dr. Kawas bringing her vast abilities, experiences, and enthusiasm to her current mission.

Follow Lawas on Pinterest

Learn more about Leen Kawas: https://www.montgomerysummit.com/speakers/leen-kawas/